抗癌药物吉西他滨纳米递送系统的研究进展
摘要
<正>吉西他滨(gemcitabine,Gem)(图1)属细胞周期特异性抗代谢类药物,外观为白色至类白色固体,易溶于水,微溶于甲醇,非极性有机溶剂中几乎不溶,主要作用于S期,是一种人工合成的胞嘧啶核苷衍生物,首先由美国礼来公司于1996年研制成功并获准上市,我国于1999年批准进口。Gem是非小细胞肺癌、胰腺癌、乳腺癌、卵巢癌、宫颈癌、子宫癌及膀胱癌等的一线化疗用药,Gem代谢产
引文
[1]Zhang YS,Tian L,Chen TZ.Application of gemcitabine in various tumors.Chongqing Med,2018,47(20):2724-2728.(in Chinese)张云嵩,田莉,陈田子.吉西他滨在多种肿瘤中的应用.重庆医学,2018,47(20):2724-2728.
[2]Moog R,Burger AM,Brandl M,et al.Change in pharmacokinetic and pharmacodynamic behavior of gemcitabine in human tumor xenografts upon entrapment in vesicular phospholipid gels.Cancer Chemother Pharmacol,2002,49(5):356-366.
[3]Yalcin TE,Ilbasmis-Tamer S,Ibisoglu B,et al.Gemcitabine hydrochloride loaded liposomes and nanoparticles:Comparison of encapsulation efficiency,drug release,particle size and cytotoxicity.Pharm Dev Technol,2018,23(1):76-86.
[4]Bornmann C,Graeser R,Esser N,et al.A new liposomal formulation of gemcitabine is active in an orthotopic mouse model of pancreatic cancer accessible to bioluminescence imaging.Cancer Chemother Pharmacol,2008,61(3):395-405.
[5]Graeser R,Bornmann C,Esser N,et al.Antimetastatic effects of liposomal gemcitabine and empty liposomes in an orthotopic mouse model of pancreatic cancer.Pancreas,2009,38(3):330-337.
[6]Xu H,Paxton JW,Wu Z.Development of long-circulating pH-sensitive liposomes to circumvent gemcitabine resistance in pancreatic cancer cells.Pharm Res,2016,33(7):1628-1637.
[7]Tong Q,Li H,Li W,et al.In vitro and in vivo anti-tumor effects of gemcitabine loaded with a new drug delivery system.J Nanosci Nanotechnol,2011,11(4):3651-3658.
[8]Li T,Chen L,Deng Y,et al.Cholesterol derivative-based liposomes for gemcitabine delivery:preparation,in vitro,and in vivo characterization.Drug Dev Ind Pharm,2017,43(12):2016-2025.
[9]Devulapally R,Paulmurugan R.Polymer nanoparticles for drug and small silencing RNA delivery to treat cancers of different phenotypes.Wiley Interdiscip Rev Nanomed Nanobiotechnol,2014,6(1):40-60.
[10]Misak HE,Asmatulu R,Gopu JS,et al.Albumin-based nanocomposite spheres for advanced drug delivery systems.Biotechnol J,2014,9(1):163-170.
[11]Kurrat R,Prenosil JE,Ramsden JJ.Kinetics of human and bovine serum albumin adsorption at silica-titania surfaces.J Colloid Interface Sci,1997,185(1):1-8.
[12]Lou J,Hu W,Tian R,et al.Optimization and evaluation of a thermoresponsive ophthalmic in situ gel containing curcumin-loaded albumin nanoparticles.Int J Nanomedicine,2014,9:2517-2525.
[13]Yu X,Di Y,Xie C,et al.An in vitro and in vivo study of gemcitabine-loaded albumin nanoparticles in a pancreatic cancer cell line.Int J Nanomedicine,2015,10:6825-6834.
[14]Buckley CD,Pilling D,Henriquez NV,et al.RGD peptides induce apoptosis by direct caspase-3 activation.Nature,1999,397(6719):534-539.
[15]Hosotani R,Kawaguchi M,Masui T,et al.Expression of integrin v3in pancreatic carcinoma:relation to MMP-2 activation and lymph node metastasis.Pancreas,2002,25(2):e30-e35.
[16]Ji S,Xu J,Zhang B,et al.RGD-conjugated albumin nanoparticles as a novel delivery vehicle in pancreatic cancer therapy.Cancer Biol Ther,2012,13(4):206-215.
[17]Wang L,An Y,Yuan C,et al.GEM-loaded magnetic albumin nanospheres modified with cetuximab for simultaneous targeting,magnetic resonance imaging,and double-targeted thermochemotherapy of pancreatic cancer cells.Int J Nanomedicine,2015,10:2507-2519.
[18]Bernkop-Schnürch A,Dünnhaupt S.Chitosan-based drug delivery systems.Eur J Pharm Biopharm,2012,81(3):463-469.
[19]Parsian M,Unsoy G,Mutlu P,et al.Loading of gemcitabine on chitosan magnetic nanoparticles increases the anti-cancer efficacy of the drug.Eur J Pharmacol,2016,784:121-128.
[20]Xu S,Xu Q,Zhou J,et al.Preparation and characterization of folate-chitosan-gemcitabine core-shell nanoparticles for potential tumor-targeted drug delivery.J Nanosci Nanotechnol,2013,13(1):129-138.
[21]Zhou J,Wang J,Xu Q,et al.Folate-chitosan-gemcitabine core-shell nanoparticles targeted to pancreatic cancer.Chin J Cancer Res,2013,25(5):527-535.
[22]Xiao J,Yu H.Gemcitabine conjugated chitosan and double antibodies(Abc-GC-gemcitabine nanoparticles)enhanced cytoplasmic uptake of gemcitabine and inhibit proliferation and metastasis in human SW1990 pancreatic cancer cells.Med Sci Monit,2017,23:1613-1620.
[23]Gong J,Chen M,Zheng Y,et al.Polymeric micelles drug delivery system in oncology.J Control Release,2012,159(3):312-323.
[24]Daman Z,Ostad S,Amini M,et al.Preparation,optimization and in vitro characterization of stearoyl-gemcitabine polymeric micelles:a comparison with its self-assembled nanoparticles.Int J Pharm,2014,468(1-2):142-151.
[25]Han H,Wang H,Chen Y,et al.Theranostic reduction-sensitive gemcitabine prodrug micelles for near-infrared imaging and pancreatic cancer therapy.Nanoscale,2016,8(1):283-291.
[26]Bildstein L,Pili B,Marsaud V,et al.Interaction of an amphiphilic squalenoyl prodrug of gemcitabine with cellular membranes.Eur J Pharm Biopharm,2011,79(3):612-620.
[27]Maksimenko A,Caron J,Mougin J,et al.Gemcitabine-based therapy for pancreatic cancer using the squalenoyl nucleoside monophosphate nanoassemblies.Int J Pharm,2015,482(1-2):38-46.
[28]Réjiba S,Reddy LH,Bigand C,et al.Squalenoyl gemcitabine nanomedicine overcomes the low efficacy of gemcitabine therapy in pancreatic cancer.Nanomedicine,2011,7(6):841-849.
[29]Kudgus RA,Szabolcs A,Khan JA,et al.Inhibiting the growth of pancreatic adenocarcinoma,in vitro,and,in vivo,through targeted treatment with designer gold nanotherapeutics.PLoS One,2013,8(3):e57522.
[30]Lin G,Mi P,Chu C,et al.Inorganic nanocarriers overcoming multidrug resistance for cancer theranostics.Adv Sci(Weinh),2016,3(11):1600134.
[31]Dilnawaz F,Singh A,Mohanty C,et al.Dual drug loaded superparamagnetic iron oxide nanoparticles for targeted cancer therapy.Biomaterials,2010,31(13):3694-3706.
[32]Lee GY,Qian WP,Wang L,et al.Theranostic nanoparticles with controlled release of gemcitabine for targeted therapy and MRI of pancreatic cancer.ACS Nano,2013,7(3):2078-2089.
[33]Parhi P,Mohanty C,Sahoo SK.Nanotechnology-based combinational drug delivery:an emerging approach for cancer therapy.Drug Discov Today,2012,17(17-18):1044-1052.
[34]Poon C,He C,Liu D,et al.Self-assembled nanoscale coordination polymers carrying oxaliplatin and gemcitabine for synergistic combination therapy of pancreatic cancer.J Control Release,2015,201:90-99.
[35]Saneja A,Dubey RD,Alam N,et al.Co-formulation of p-glycoprotein substrate and inhibitor in nanocarriers:an emerging strategy for cancer chemotherapy.Curr Cancer Drug Targets,2014,14(5):419-433.
[36]Zhang Y,Peng L,Mumper RJ,et al.Combinational delivery of c-myc siRNA and nucleoside analogs in a single,synthetic nanocarrier for targeted cancer therapy.Biomaterials,2013,34(33):8459-8468.
[37]Zhao X,Li F,Li Y,et al.Co-delivery of HIF1αsi RNA and gemcitabine via biocompatible lipid-polymer hybrid nanoparticles for effective treatment of pancreatic cancer.Biomaterials,2015,46:13-25.
[2]Moog R,Burger AM,Brandl M,et al.Change in pharmacokinetic and pharmacodynamic behavior of gemcitabine in human tumor xenografts upon entrapment in vesicular phospholipid gels.Cancer Chemother Pharmacol,2002,49(5):356-366.
[3]Yalcin TE,Ilbasmis-Tamer S,Ibisoglu B,et al.Gemcitabine hydrochloride loaded liposomes and nanoparticles:Comparison of encapsulation efficiency,drug release,particle size and cytotoxicity.Pharm Dev Technol,2018,23(1):76-86.
[4]Bornmann C,Graeser R,Esser N,et al.A new liposomal formulation of gemcitabine is active in an orthotopic mouse model of pancreatic cancer accessible to bioluminescence imaging.Cancer Chemother Pharmacol,2008,61(3):395-405.
[5]Graeser R,Bornmann C,Esser N,et al.Antimetastatic effects of liposomal gemcitabine and empty liposomes in an orthotopic mouse model of pancreatic cancer.Pancreas,2009,38(3):330-337.
[6]Xu H,Paxton JW,Wu Z.Development of long-circulating pH-sensitive liposomes to circumvent gemcitabine resistance in pancreatic cancer cells.Pharm Res,2016,33(7):1628-1637.
[7]Tong Q,Li H,Li W,et al.In vitro and in vivo anti-tumor effects of gemcitabine loaded with a new drug delivery system.J Nanosci Nanotechnol,2011,11(4):3651-3658.
[8]Li T,Chen L,Deng Y,et al.Cholesterol derivative-based liposomes for gemcitabine delivery:preparation,in vitro,and in vivo characterization.Drug Dev Ind Pharm,2017,43(12):2016-2025.
[9]Devulapally R,Paulmurugan R.Polymer nanoparticles for drug and small silencing RNA delivery to treat cancers of different phenotypes.Wiley Interdiscip Rev Nanomed Nanobiotechnol,2014,6(1):40-60.
[10]Misak HE,Asmatulu R,Gopu JS,et al.Albumin-based nanocomposite spheres for advanced drug delivery systems.Biotechnol J,2014,9(1):163-170.
[11]Kurrat R,Prenosil JE,Ramsden JJ.Kinetics of human and bovine serum albumin adsorption at silica-titania surfaces.J Colloid Interface Sci,1997,185(1):1-8.
[12]Lou J,Hu W,Tian R,et al.Optimization and evaluation of a thermoresponsive ophthalmic in situ gel containing curcumin-loaded albumin nanoparticles.Int J Nanomedicine,2014,9:2517-2525.
[13]Yu X,Di Y,Xie C,et al.An in vitro and in vivo study of gemcitabine-loaded albumin nanoparticles in a pancreatic cancer cell line.Int J Nanomedicine,2015,10:6825-6834.
[14]Buckley CD,Pilling D,Henriquez NV,et al.RGD peptides induce apoptosis by direct caspase-3 activation.Nature,1999,397(6719):534-539.
[15]Hosotani R,Kawaguchi M,Masui T,et al.Expression of integrin v3in pancreatic carcinoma:relation to MMP-2 activation and lymph node metastasis.Pancreas,2002,25(2):e30-e35.
[16]Ji S,Xu J,Zhang B,et al.RGD-conjugated albumin nanoparticles as a novel delivery vehicle in pancreatic cancer therapy.Cancer Biol Ther,2012,13(4):206-215.
[17]Wang L,An Y,Yuan C,et al.GEM-loaded magnetic albumin nanospheres modified with cetuximab for simultaneous targeting,magnetic resonance imaging,and double-targeted thermochemotherapy of pancreatic cancer cells.Int J Nanomedicine,2015,10:2507-2519.
[18]Bernkop-Schnürch A,Dünnhaupt S.Chitosan-based drug delivery systems.Eur J Pharm Biopharm,2012,81(3):463-469.
[19]Parsian M,Unsoy G,Mutlu P,et al.Loading of gemcitabine on chitosan magnetic nanoparticles increases the anti-cancer efficacy of the drug.Eur J Pharmacol,2016,784:121-128.
[20]Xu S,Xu Q,Zhou J,et al.Preparation and characterization of folate-chitosan-gemcitabine core-shell nanoparticles for potential tumor-targeted drug delivery.J Nanosci Nanotechnol,2013,13(1):129-138.
[21]Zhou J,Wang J,Xu Q,et al.Folate-chitosan-gemcitabine core-shell nanoparticles targeted to pancreatic cancer.Chin J Cancer Res,2013,25(5):527-535.
[22]Xiao J,Yu H.Gemcitabine conjugated chitosan and double antibodies(Abc-GC-gemcitabine nanoparticles)enhanced cytoplasmic uptake of gemcitabine and inhibit proliferation and metastasis in human SW1990 pancreatic cancer cells.Med Sci Monit,2017,23:1613-1620.
[23]Gong J,Chen M,Zheng Y,et al.Polymeric micelles drug delivery system in oncology.J Control Release,2012,159(3):312-323.
[24]Daman Z,Ostad S,Amini M,et al.Preparation,optimization and in vitro characterization of stearoyl-gemcitabine polymeric micelles:a comparison with its self-assembled nanoparticles.Int J Pharm,2014,468(1-2):142-151.
[25]Han H,Wang H,Chen Y,et al.Theranostic reduction-sensitive gemcitabine prodrug micelles for near-infrared imaging and pancreatic cancer therapy.Nanoscale,2016,8(1):283-291.
[26]Bildstein L,Pili B,Marsaud V,et al.Interaction of an amphiphilic squalenoyl prodrug of gemcitabine with cellular membranes.Eur J Pharm Biopharm,2011,79(3):612-620.
[27]Maksimenko A,Caron J,Mougin J,et al.Gemcitabine-based therapy for pancreatic cancer using the squalenoyl nucleoside monophosphate nanoassemblies.Int J Pharm,2015,482(1-2):38-46.
[28]Réjiba S,Reddy LH,Bigand C,et al.Squalenoyl gemcitabine nanomedicine overcomes the low efficacy of gemcitabine therapy in pancreatic cancer.Nanomedicine,2011,7(6):841-849.
[29]Kudgus RA,Szabolcs A,Khan JA,et al.Inhibiting the growth of pancreatic adenocarcinoma,in vitro,and,in vivo,through targeted treatment with designer gold nanotherapeutics.PLoS One,2013,8(3):e57522.
[30]Lin G,Mi P,Chu C,et al.Inorganic nanocarriers overcoming multidrug resistance for cancer theranostics.Adv Sci(Weinh),2016,3(11):1600134.
[31]Dilnawaz F,Singh A,Mohanty C,et al.Dual drug loaded superparamagnetic iron oxide nanoparticles for targeted cancer therapy.Biomaterials,2010,31(13):3694-3706.
[32]Lee GY,Qian WP,Wang L,et al.Theranostic nanoparticles with controlled release of gemcitabine for targeted therapy and MRI of pancreatic cancer.ACS Nano,2013,7(3):2078-2089.
[33]Parhi P,Mohanty C,Sahoo SK.Nanotechnology-based combinational drug delivery:an emerging approach for cancer therapy.Drug Discov Today,2012,17(17-18):1044-1052.
[34]Poon C,He C,Liu D,et al.Self-assembled nanoscale coordination polymers carrying oxaliplatin and gemcitabine for synergistic combination therapy of pancreatic cancer.J Control Release,2015,201:90-99.
[35]Saneja A,Dubey RD,Alam N,et al.Co-formulation of p-glycoprotein substrate and inhibitor in nanocarriers:an emerging strategy for cancer chemotherapy.Curr Cancer Drug Targets,2014,14(5):419-433.
[36]Zhang Y,Peng L,Mumper RJ,et al.Combinational delivery of c-myc siRNA and nucleoside analogs in a single,synthetic nanocarrier for targeted cancer therapy.Biomaterials,2013,34(33):8459-8468.
[37]Zhao X,Li F,Li Y,et al.Co-delivery of HIF1αsi RNA and gemcitabine via biocompatible lipid-polymer hybrid nanoparticles for effective treatment of pancreatic cancer.Biomaterials,2015,46:13-25.